Your Testosterone Is "Normal"—But Is It Normal for You? A Woman's Guide to Testosterone Labs

Your testosterone came back "normal."

You are still exhausted. Your strength is changing. Your motivation feels flatter. Your sexual desire has apparently entered witness protection, and orgasms may require a full calendar invitation, perfect lighting, eight uninterrupted hours, and an act of Congress.

But the number is inside the laboratory range, so you are told testosterone cannot possibly be part of the conversation.

This happens to women all the time.

First, testosterone is treated as though it belongs exclusively to men. It does not.

Then, if a woman is fortunate enough to have it tested, one small number is compared with a very wide reference interval and declared "fine"—often without measuring SHBG, calculating free testosterone, considering age or hormone therapy, or asking whether the testing method is accurate at female concentrations.

Women naturally produce testosterone through the ovaries and adrenal androgen pathways. It plays roles in sexual desire, arousal, genital tissue response, muscle, bone, mood, motivation, and overall physiology.

But interpreting a woman's testosterone is not as simple as looking for a red flag beside the result.

In fact, the "normal testosterone" paradox may be even more complicated in women than it is in men.

Most laboratory reference intervals are statistical.

The laboratory measures testosterone in a selected group, then defines an interval that commonly contains the central 95% of those results. The lower boundary may be near the 2.5th percentile and the upper boundary near the 97.5th percentile.

That sounds scientific—and it is—but the usefulness of the result depends on the details.

For a woman's testosterone range, we should ask: What ages were included? Were the women premenopausal, perimenopausal, or postmenopausal? Were they using hormonal birth control or hormone therapy? Did they still have ovaries? What phase of the menstrual cycle were they in? Were women with obesity, insulin resistance, or other conditions included? Was testosterone measured by immunoassay or LC-MS/MS? Was the lower end of the range close to the assay's detection limit?

If a laboratory combines women with very different ages, ovarian states, medications, and SHBG levels, the resulting range may be statistically valid for that group while still being clinically unhelpful for the individual woman in front of us.

"Normal" does not necessarily mean: normal for your age, normal for your previous baseline, normal for your symptoms, normal for your SHBG level, adequately measured, or proof that testosterone is irrelevant.

It means the reported result fits that laboratory's interval. That is a starting point—not a full assessment.

Men's guidelines commonly discuss diagnostic thresholds such as 264 or 300 ng/dL. Women do not have an equivalent, universally accepted testosterone cutoff that diagnoses a clinical androgen-deficiency syndrome.

That is not because testosterone is unimportant in women. It is because symptoms such as low desire, fatigue, reduced motivation, and changes in strength have many possible causes; blood testosterone levels do not consistently separate women with sexual dysfunction from women without it; assays have historically struggled to measure the much lower concentrations found in women; reference data across the female lifespan remain less complete; and total testosterone does not reveal the effect of SHBG.

The Global Consensus Position Statement and the International Society for the Study of Women's Sexual Health both state that there is no testosterone blood-level cutoff that reliably identifies women with hypoactive sexual desire disorder, or HSDD.

The Endocrine Society has also advised against diagnosing a broad "androgen deficiency syndrome" in otherwise healthy women because there is not yet a well-defined syndrome linked to a specific laboratory threshold.

This creates a frustrating paradox: a woman can have a laboratory range, but the bottom of that range is not a proven line between "enough testosterone" and "not enough testosterone" for sexual function or overall well-being.

The number still matters. It simply cannot make the diagnosis by itself.

For years, many testosterone assays were designed primarily around the much higher concentrations seen in men.

Trying to measure a woman's testosterone with a method optimized for male levels can be like trying to weigh a paperclip on a bathroom scale. The scale may display a number, but that does not mean it is precise enough for the job.

Traditional automated immunoassays are convenient and may perform reasonably at typical male concentrations. At the low concentrations found in women, children, and severely hypogonadal men, they may lack sensitivity, specificity, and precision.

LC-MS/MS testing improved the ability to separate testosterone from similar molecules and measure much lower concentrations accurately. The CDC's Hormone Standardization Program has also worked to improve calibration and comparability among laboratories.

This matters because a historical result and a modern result may differ for reasons that have nothing to do with a woman's physiology: a different assay, better sensitivity, new calibration, a different reference population, a new test code, or a different performing laboratory.

The reference range may evolve because the science of measurement evolved—not because women's hormones changed overnight.

Not exactly.

Estradiol changes dramatically around the menopausal transition, but testosterone follows a different pattern.

Research has found that women's total and free testosterone tend to decline with age, with some of the steepest changes occurring during the earlier reproductive decades. In one large community study, natural menopause itself did not create an abrupt independent drop in testosterone among women ages 45 to 54.

The postmenopausal ovary can continue contributing to androgen production. Women who have both ovaries surgically removed may have lower testosterone than women who reach menopause naturally.

That means: a 48-year-old woman's testosterone should not automatically be interpreted as though she were 25; testosterone does not necessarily fall off a cliff on the official date of menopause; age, ovarian function, adrenal precursors, medications, and SHBG all affect the pattern; and surgical menopause is not hormonally identical to natural menopause.

Female hormone physiology refuses to fit into a neat little box. She has never respected boxes.

Imagine your bloodstream is a city and testosterone is traveling through it.

Total testosterone counts nearly all testosterone in circulation: testosterone tightly bound to SHBG, testosterone loosely bound to albumin and other proteins, and testosterone circulating freely. It tells us how much testosterone is present overall. It does not tell us how much is tightly held or readily available. Total testosterone is still useful—but a normal total does not guarantee a normal free level.

SHBG (sex hormone-binding globulin) is made primarily by the liver and binds testosterone tightly. Picture SHBG as an armored vehicle with locked doors. Testosterone riding inside still counts toward the total—but it is not readily released. SHBG can rise with oral estrogen, many combined hormonal contraceptives, hyperthyroidism, some liver conditions, certain anticonvulsants, and lower body weight. SHBG can fall with insulin resistance, obesity, type 2 diabetes, metabolic fatty liver disease, hypothyroidism, androgen exposure, and some glucocorticoids.

This is why two women can have the same total testosterone and very different free-testosterone exposure. If we never measure SHBG, we miss the plot twist.

Albumin also carries testosterone, but the binding is much looser—the rideshare driver. Testosterone is technically in the car, but it can be dropped off more readily than testosterone locked inside SHBG.

Free testosterone is the small portion not attached to a circulating protein—the testosterone walking freely through the city, able to reach tissues without first separating from a carrier.

Bioavailable testosterone generally includes free testosterone plus testosterone loosely bound to albumin. It is sometimes described as non-SHBG-bound testosterone. Total testosterone counts everyone. Free and bioavailable testosterone help describe who may actually be able to get where they need to go.

Free testosterone may be the most revealing result in the right woman—especially when SHBG is altered.

Consider two examples. Woman A has a total testosterone inside the laboratory interval, but she uses oral estrogen or a combined birth-control pill, and her SHBG is high. Her calculated free testosterone is very low. Looking only at total testosterone may hide the effect of the elevated binding protein.

Woman B has a total testosterone near the bottom of the interval. She has insulin resistance and a low SHBG. Her free fraction may be less reduced than the total result suggests. Her low SHBG is also a metabolic clue that deserves attention rather than simply becoming a reason to increase testosterone.

Free testosterone can help us understand the story, but it still cannot diagnose HSDD, fatigue, or a generalized female testosterone-deficiency syndrome by itself.

And there is another catch: free testosterone is difficult to measure accurately. That means a beautifully precise-looking result with two decimal places may still be misleading if it came from the wrong method.

Equilibrium dialysis is considered the benchmark method for free-testosterone measurement. It is technically difficult, relatively expensive, and not routinely available everywhere.

Free testosterone can also be estimated from total testosterone, SHBG, albumin, and a validated calculation. This is often clinically useful when the total testosterone and SHBG measurements are reliable.

Some laboratories report "direct free testosterone" using an analog immunoassay. These methods have important accuracy limitations and are not interchangeable with equilibrium dialysis or a well-validated calculation.

For women, the first requirement is an accurate total testosterone—preferably by LC-MS/MS when values are expected to be low—plus SHBG and albumin when free testosterone is being calculated.

The words printed beside the result matter: measured or calculated? LC-MS/MS or immunoassay? What units? Which reference interval? Which performing laboratory?

Laboratories may use different instruments, antibodies, calibration materials, LC-MS/MS procedures, free-testosterone formulas, detection limits, reference populations, and age and menopausal categories.

These differences become especially important at female testosterone concentrations because a small numerical change may represent a large percentage difference.

The draw location itself is not the main scientific issue. However, a sample collected at one location may be routed to a different regional or specialty performing laboratory than a sample collected elsewhere. A different performing site or test code can mean a different method and reference interval.

When following a trend, consistency helps: use the same laboratory when possible, use the same test code and method, collect at a similar time of day, if cycling document cycle timing, keep the interval from any testosterone dose consistent, and record changes in birth control, oral estrogen, thyroid medication, or other hormones.

Do not assume a change from 18 to 24 means your ovaries suddenly had a productive week if the two numbers came from different methods.

Oral estrogen passes through the liver and can raise SHBG. Many combined hormonal contraceptives can also increase SHBG.

When SHBG rises: total testosterone may remain normal or even look higher, the free fraction may decrease, and a woman can have a "normal" total result that does not match the clinical picture.

This does not mean oral estrogen or birth control is automatically wrong. It means the medication must be included in the interpretation.

Route matters too. Transdermal estrogen generally has less effect on liver production of SHBG than oral estrogen. In selected women with HSDD who are using oral estrogen, clinicians may consider whether the estrogen route is contributing to high SHBG before simply adding more testosterone.

The answer is not always "more hormone." Sometimes the answer is understanding what the current hormones are doing.

Guidelines are appropriately cautious because female testosterone research and long-term safety data remain more limited than they should be.

The broad consensus is: no testosterone blood-level cutoff diagnoses HSDD; low desire requires a biopsychosocial and medical assessment, not only a lab; the best-supported indication for systemic testosterone therapy is HSDD in appropriately evaluated postmenopausal women; evidence in premenopausal women remains more limited; in the United States, there is no FDA-approved testosterone product specifically formulated for women; if therapy is used, dosing should remain within the physiologic premenopausal female range and be monitored for clinical response and androgenic adverse effects; and total testosterone is used as a baseline and safety-monitoring tool—not as a treatment target to chase higher.

This is one place where clinical nuance matters. "A blood test cannot diagnose HSDD" does not mean labs are useless. Labs help us identify an unexpectedly high level, evaluate SHBG and binding, establish a baseline, monitor therapy and avoid excessive exposure, recognize assay problems, and place testosterone within the broader hormonal and metabolic pattern.

The laboratory informs the decision. It does not replace the conversation.

Women are often carrying jobs, children, schedules, aging parents, housework, relationship stress, and the invisible task of remembering what everyone else forgot.

Of course desire may be affected.

But "you are busy" should not become another way to dismiss a woman who knows something has changed.

A thoughtful evaluation may also consider: perimenopause or menopause, estradiol-related symptoms and vaginal tissue changes, pain with sex, sleep deprivation or sleep apnea, thyroid dysfunction, iron, B12, or vitamin D deficiency, depression, anxiety, and chronic stress, medication effects including some antidepressants, insulin resistance and metabolic health, pelvic-floor dysfunction, relationship context, and surgical removal of the ovaries.

Sometimes testosterone is part of the pattern. Sometimes it is not. Often several pieces are connected.

At SomneX Health, we do not chase a number while ignoring the woman attached to it.

Can a blood test diagnose low testosterone in a woman? There is no universally accepted testosterone cutoff that diagnoses a broad female androgen-deficiency syndrome or separates women with HSDD from women without it. Laboratory testing still provides important context, helps identify excess, and supports safe monitoring.

Can my total testosterone be normal while my free testosterone is low? Yes. High SHBG can keep total testosterone inside the reference interval while reducing the free fraction. Oral estrogen, some birth-control pills, thyroid status, liver conditions, and other factors can affect SHBG.

Is free testosterone more important than total testosterone in women? Free testosterone may better explain the pattern when SHBG is abnormal, but it must be obtained using a reliable method. Total testosterone remains important as a baseline and safety measurement, particularly during therapy.

What is the best way to measure testosterone in women? An accurate total testosterone measured by LC-MS/MS is preferred when concentrations are expected to be low. SHBG and albumin can be used to calculate free testosterone. Direct analog free-testosterone assays may be unreliable.

Does testosterone suddenly drop at menopause? Not necessarily. Testosterone tends to change with age and ovarian-adrenal function, but natural menopause does not always cause an abrupt testosterone crash. Surgical removal of both ovaries may have a more significant effect.

Why did my testosterone result change at a different laboratory? The laboratories may use different assays, calibration, formulas, units, performing sites, or reference populations. At the low levels found in women, method differences can be especially noticeable.

Does a low result automatically mean I need testosterone? No. Symptoms, medications, sleep, sexual pain, relationship context, estrogen status, metabolic health, contraindications, and treatment goals all matter. A low-looking number should prompt interpretation—not an automatic prescription.